Off-target effects of oral anticoagulants - vascular effects of vitamin K antagonist and non-vitamin K antagonist oral anticoagulant dabigatran etexilate.
Rick H van GorpIngrid DijkgraafVanessa BrökerMatthias BauwensPeter LeendersDanyel JennenMarc R DweckJan BuceriusJacco J BriedéJoanne van RynVincent BrandenburgFelix MottaghyHenri M H SpronkChris P ReutelingspergerLeon J SchurgersPublished in: Journal of thrombosis and haemostasis : JTH (2021)
Warfarin aggravates atherosclerotic disease activity, increasing plaque inflammation, active calcification, and plaque progression. Dabigatran lacks undesired vascular side effects and reveals beneficial effects on atherosclerosis progression and calcification. The choice of anticoagulation impacts atherosclerotic disease by differential off target effect. Future clinical studies should test whether this beneficial effect also applies to patients.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- disease activity
- end stage renal disease
- chronic kidney disease
- rheumatoid arthritis
- systemic lupus erythematosus
- direct oral anticoagulants
- venous thromboembolism
- coronary artery disease
- oxidative stress
- ankylosing spondylitis
- ejection fraction
- cardiovascular disease
- newly diagnosed
- juvenile idiopathic arthritis
- prognostic factors
- type diabetes